You are living in denial if you expect the share price to hit a dollar on UK approval alone. It ain’t happening without UK reimbursement approval and a successful FDA BLA submission. You can bet none of these milestones are happening in 2026.
So it will be shorted to ground very quickly even if we get a nice spike to .40 or .50 range, which also looks highly unlikely if the MHRA decision slips to late Q1 or after because the stock would have already slipped to low teens by then.
Also, shorts already likely know given the trading pattern, but it will become 100% clear that there is no big pharma deal as soon as any major financing deal is done on a spike or a request for increase in authorized share count.
Market Data 
Markets 
AI
